Previous Close | 120.14 |
Open | 119.95 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 119.95 - 119.95 |
52 Week Range | 110.25 - 140.21 |
Volume | 100 |
Avg. Volume | 3,020 |
Market Cap | 99.962B |
Beta | 1.26 |
PE Ratio (TTM) | 11.64 |
EPS (TTM) | 10.30 |
Earnings Date | N/A |
Forward Dividend & Yield | 2.94 (2.48%) |
Ex-Dividend Date | 2017-04-28 |
1y Target Est | N/A |
Russia's antitrust regulator FAS has approved Bayer's planned takeover of Monsanto, the German drugs and crop chemicals maker said, as it enters the home stretch to closing the $62.5 billion deal. Russia was one of the few jurisdictions to be won over, after the European Commission last month gave conditional clearance and after a source said Bayer struck an agreement in principle with the U.S. Department of Justice. "Bayer has agreed to enable the transfer of defined technologies to Russian recipients in the area of seeds breeding and digital farming for a period of five years," the company said in a statement.
Procter & Gamble, which is buying the Merck unit, was previously reported to be in talks to acquire Pfizer's consumer healthcare business.
Russia's antitrust regulator FAS has approved Bayer's planned takeover of Monsanto , the German drugs and crop chemicals maker said, as it enters the home stretch to closing the $62.5 billion deal. Russia was one of the few jurisdictions to be won over, after the European Commission last month gave conditional clearance and after a source said Bayer struck an agreement in principle with the U.S. Department of Justice.
Russia's antitrust regulator FAS has approved Bayer's planned $62.5 billion takeover of Monsanto, a Bayer spokesman said on Friday.
In March 2018, the FDA accepted Exelixis’s (EXEL) supplemental New Drug Application (or sNDA) for Cabometyx as a therapy for the treatment of individuals with advanced hepatocellular carcinoma (or HCC) who have previously undergone therapy. Exelixis’s sNDA was based on the results of its Phase 3 CELESTIAL trial. In October 2017, an independent data-monitoring committee recommended that Exelixis stop its CELESTIAL efficacy trial after a review of the second planned interim analysis, wherein Cabometyx demonstrated statistically significant and clinically meaningful progress in overall survival compared to the placebo in individuals who had already been treated for advanced HCC.
Bayer (BAYRY) will divest its 3.6% stake to Singapore's state investment company Temasek for total gross proceeds of ???3 billion.
The U.S. Department of Justice is poised to give Bayer the go-ahead for its multibillion-dollar takeover of Monsanto, nearly two years after the company made its first approach in May 2016. Dow Jones explains....
Bayer said late Monday that investment company Temasek has signed an agreement to increase its share capital in the German company.
One sign that things are moving in the right direction is Singaporean sovereign wealth fund Temasek’s decision to take a 3.6 per cent stake via newly created shares in Bayer. Bayer will need all the cash it can get. Buying Monsanto should cost $66bn (€53.5bn).
The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday: ** Shire, the London-listed rare diseases specialist that is a potential takeover target for Japan's Takeda Pharmaceutical, is selling its oncology business to unlisted French drugmaker Servier for $2.4 billion. ** Pebblebrook Hotel Trust has sweetened its $3 billion-plus offer to buy U.S. peer LaSalle Hotel Properties after the owner of high-end locations including 'W' Los Angeles saw an initial bid rebuffed last month.
German drugmaker Bayer (BAYGn.DE) is raising 3 billion euros (2.6 billion pounds) towards its planned $62.5 billion takeover of seed maker Monsanto (MON.N) by selling a 3.6 percent stake to Singapore's state investment company Temasek. Bayer said it had struck a deal with Temasek [TEM.UL] under which it would issue shares with an entitlement to dividends as of January 1, 2017 at an at-market price. Together with its existing holding in Bayer, Temasek would own about 4 percent in Bayer after the transaction.
The U.S. Department of Justice's move to approve German pharma company Bayer AG's acquisition of U.S.-based Monsanto Company (NYSE: MON ) prompted at least one Wall Street analyst to turn bearish on the ...
Germany's Bayer plans to sell its digital farming business to BASF as part of changes to concessions it has offered to win over antitrust regulators for its proposed takeover of Monsanto. Bayer, which had previously only agreed to grant a licence to competitors, said on Wednesday that as part of the changes agreed with the European Commission it would retain a licence to certain digital farming applications. Digital farming, which combines sensors, software and precision machines, is still in its infancy but all the large players in the seeds and pesticides industry are developing digital offerings.
Germany's Bayer (BAYGn.DE) plans to sell its digital farming business to BASF (BASFn.DE) as part of changes to concessions it has offered to win over antitrust regulators for its proposed takeover of Monsanto (MON.N). Bayer, which had previously only agreed to grant a license to competitors, said on Wednesday that as part of the changes agreed with the European Commission it would retain a license to certain digital farming applications. Digital farming, which combines sensors, software and precision machines, is still in its infancy but all the large players in the seeds and pesticides industry are developing digital offerings.
BRUSSELS (Reuters) - The European Commission said on Wednesday it had approved a request by Germany's Bayer (BAYGn.DE) to make two modifications to the commitments it made to get approval for its purchase ...
The European Commission said on Wednesday it had approved a request by Germany's Bayer to make two modifications to the commitments it made to get approval for its purchase of U.S. group Monsanto. Under the new proposal, Bayer has asked to sell its Bayer seed treatment assets and products unit as well as its global digital agriculture assets to BASF. The Commission, which oversees competition in the European Union, said the commitments as modified would be at least as effective to ease competition concerns as the previous proposal.
FDA puts restriction on the sale of Bayer's (BAYRY) implanted birth control device Essure.
European stocks on Tuesday close at their highest level in about a month, with sharp gains registered at all of the major bourses, as China’s premier bolstered hopes that a global trade war can be averted....
Bayer AG is close to winning U.S. antitrust approval to buy Monsanto Co., according to a person familiar with the matter, a move that would lift the last major hurdle to completing a $66 billion deal that ...
Bayer (BAYGn.DE) shares jumped nearly 5 percent on Tuesday following a media report that the U.S. Justice Department will allow the German drugs and pesticides group to acquire Monsanto (MON.N) in a $62.5 billion (44.14 billion pounds) deal. The Justice Department reached an agreement in principle with Bayer and Monsanto in recent days after the companies agreed to sell more assets, the Wall Street Journal said late on Monday, citing people familiar with the matter. Under the deal, Bayer agreed to sell additional seed and treatment assets to BASF (BASFn.DE) and agreed to make concessions related to digital agriculture, it said.
Bayer's long-running takeover of Monsanto is starting to look more attractive.
Bayer (BAYGn.DE) shares jumped nearly 5 percent on Tuesday following a media report that the U.S. Justice Department will allow the German drugs and pesticides group to acquire Monsanto (MON.N) in a $62.5 billion deal. The Justice Department reached an agreement in principle with Bayer and Monsanto in recent days after the companies agreed to sell more assets, the Wall Street Journal said late on Monday, citing people familiar with the matter. Under the deal, Bayer agreed to sell additional seed and treatment assets to BASF (BASFn.DE) and agreed to make concessions related to digital agriculture, it said.
The Justice Department will allow Bayer’s megadeal to acquire Monsanto after the companies pledged to sell off additional assets to secure government antitrust approval.
The U.S. Justice Department will allow German drugs and pesticides group Bayer AG to acquire Monsanto Co in a $62.5 billion deal, after the companies agreed to sell more assets to win antitrust approval, the Wall Street Journal has reported, sending shares of Monsanto, the world's biggest seed company, close to a four-year high. Sonia Legg reports